These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25797367)

  • 21. Assessing the safety of influenza vaccination in specific populations: children and the elderly.
    Rowhani-Rahbar A; Klein NP; Baxter R
    Expert Rev Vaccines; 2012 Aug; 11(8):973-84. PubMed ID: 23002978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of fatal adverse events after H1N1 influenza vaccination.
    Nakada H; Narimatsu H; Tsubokura M; Murashige N; Matsumura T; Kodama Y; Kishi Y; Kami M
    Clin Infect Dis; 2010 Jun; 50(11):1548-9. PubMed ID: 20433361
    [No Abstract]   [Full Text] [Related]  

  • 23. The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis.
    Huang WT; Huang WI; Huang YW; Hsu CW; Chuang JH
    Vaccine; 2012 Mar; 30(12):2168-72. PubMed ID: 22265861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
    Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
    Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system.
    Newes-Adeyi G; Greece J; Bozeman S; Walker DK; Lewis F; Gidudu J
    Vaccine; 2012 Feb; 30(6):1050-5. PubMed ID: 22200501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
    Choe YJ; Cho H; Song KM; Kim JH; Han OP; Kwon YH; Bae GR; Lee HJ; Lee JK
    Jpn J Infect Dis; 2011; 64(4):297-303. PubMed ID: 21788704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe.
    Pérez-Romero P; Bulnes-Ramos A; Torre-Cisneros J; Gavaldá J; Aydillo TA; Moreno A; Montejo M; Fariñas MC; Carratalá J; Muñoz P; Blanes M; Fortún J; Suárez-Benjumea A; López-Medrano F; Barranco JL; Peghin M; Roca C; Lara R; Cordero E; ;
    Clin Microbiol Infect; 2015 Nov; 21(11):1040.e11-8. PubMed ID: 26232537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.
    Tavares F; Delaigle A; Slavin D; Bauchau V; Fries L; Seifert H
    Vaccine; 2011 Aug; 29(37):6402-7. PubMed ID: 21527305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015.
    Pillsbury A; Cashman P; Leeb A; Regan A; Westphal D; Snelling T; Blyth C; Crawford N; Wood N; Macartney K;
    Euro Surveill; 2015; 20(43):. PubMed ID: 26536867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009-2010 influenza vaccination in the Netherlands.
    van der Maas NA; Godefrooij S; Vermeer-de Bondt PE; de Melker HE; Kemmeren J
    Hum Vaccin Immunother; 2016 Apr; 12(4):1027-32. PubMed ID: 26809939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
    Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
    Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.
    Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M
    Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
    Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
    Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands.
    de Vries L; van Hunsel F; Cuppers-Maarschalkerweerd B; van Puijenbroek E; van Grootheest K
    Birth Defects Res A Clin Mol Teratol; 2014 Oct; 100(10):731-8. PubMed ID: 24706475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.
    Muhammad R; Haber P; Broder K; Leroy Z; Ball R; Braun MM; Davis RL; McMahon AW
    Pediatr Infect Dis J; 2011 Jan; 30(1):e1-8. PubMed ID: 21042229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
    Aichinger G; Grohmann-Izay B; van der Velden MV; Fritsch S; Koska M; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
    Clin Vaccine Immunol; 2015 Jan; 22(1):46-55. PubMed ID: 25355797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Annual report: surveillance of adverse events following immunisation in Australia, 2004.
    Lawrence GL; Boyd I; McIntyre PB; Isaacs D
    Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.